Skip to contents

Scott D. Solomon, MD
Senior Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Director, Noninvasive Cardiology

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115

Email: ssolomon@rics.bwh.harvard.edu



Research Narrative:

Scott D. Solomon, MD is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women’s Hospital. He received his A.B. from Williams College and his M.D. from Harvard Medical School.


Dr. Solomon’s research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction. He has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials. He and his research group have played a leading role in many international clinical trials in heart failure, hypertension and myocardial infarction, including the SAVE, HEART, VALIANT, CHARM, PEACE, OVERTURE, MADIT- CRT, ALOFT, ALLAY, TREAT, RED-HF, ALTITUDE, FREEDOM, TOPCAT trials. He led the NIH- sponsored Celecoxib Cross-trials Safety Study which directly informed regulatory agencies about the safety of widely used non-steroidal anti-inflammatory agents. He directs the Cardiac Imaging Center for the NHLBI Atherosclerosis Risk in Communities (ARIC) study and Hispanic Community Health Study – Study of Latinos (HCHS-SOL), the two largest NIH cohort studies. He is PI of the NHLBI sponsored INVESTED trial studying the role of inluenza vaccine in preventing morbidity and mortality in high-risk cardiovascular patients.

Dr. Solomon has recently studied the role for angiotensin receptor neprilysin inhibition in heart failure. He served as member of the executive committee for the PARADIGM-HF trial, led the first successful Phase II trial in heart failure with preserved ejection fraction and is currently leading the ongoing PARAGON-HF outcomes trial in HFpEF.

Dr. Solomon leads a research group consisting of 6 faculty members, 8 research fellows and 30 support staff. He currently receives, or has received, extensive research support from the NIH and multiple industry sponsors. He has directed the Harvard Medical School Cardiovascular Clerkship and the Echocardiography training program at Brigham and Women’s Hospital. He has authored more than 400 peer-reviewed articles, reviews and editorials, two textbooks of cardiac imaging, and the Echocardiograph/Imaging sections for the 10 th edition of Braunwald’s Heart Disease and 19 th edition Harrison’s Principles of Internal Medicine. He is listed by Thomson-Reuters as one of the most highly cited scientists in the past 10 years. He is a Cardiology Section Editor at UpToDate and International Associate Editor at The European Heart Journal.


Education:
Harvard Medical School , 1986, MD
Williams College, 1981, AB

Publications (Pulled from Harvard Catalyst Profiles):

1. Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 Apr 14; 38(15):1132-1143.

2. Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017 Apr 14; 38(15):1119-1127.

3. Lam CS, Solomon SD. Fussing Over the Middle Child: Heart Failure With Mid-Range Ejection Fraction. Circulation. 2017 Apr 04; 135(14):1279-1280.

4. Anand IS, Claggett B, Liu J, Shah AM, Rector TS, Shah SJ, Desai AS, O'Meara E, Fleg JL, Pfeffer MA, Pitt B, Solomon SD. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. JACC Heart Fail. 2017 Apr; 5(4):241-252.

5. Seidelmann SB, Vardeny O, Claggett B, Yu B, Shah AM, Ballantyne CM, Selvin E, MacRae CA, Boerwinkle E, Solomon SD. An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. J Am Heart Assoc. 2017 Mar 24; 6(4).

6. Biering-Sørensen T, Shah SJ, Anand I, Sweitzer N, Claggett B, Liu L, Pitt B, Pfeffer MA, Solomon SD, Shah AM. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail. 2017 Mar 21.

7. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017 May; 5(5):333-340.

8. Abdul-Rahim AH, Perez AC, MacIsaac RL, Jhund PS, Claggett BL, Carson PE, Komajda M, McKelvie RS, Zile MR, Swedberg K, Yusuf S, Pfeffer MA, Solomon SD, Lip GYH, Lees KR, McMurray JJV. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. Eur Heart J. 2017 Mar 07; 38(10):742-750.

9. Foster MC, Weiner DE, Bostom AG, Carpenter MA, Inker LA, Jarolim P, Joseph AA, Kusek JW, Pesavento T, Pfeffer MA, Rao M, Solomon SD, Levey AS. Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial. Am J Transplant. 2017 Mar 03.

10. Vardeny O, Solomon SD. Influenza vaccination: a one-shot deal to reduce cardiovascular events. Eur Heart J. 2017 Feb 01; 38(5):334-337.